Osimertinib in first line setting: for Asian patients
Editorial Commentary

Osimertinib in first line setting: for Asian patients

Keisuke Onoi#, Yoshiko Kaneko#, Junji Uchino

Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

#These authors contributed equally to this work.

Correspondence to: Dr. Junji Uchino. Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, kawaramachi-dori, Kamigyo-ku, Kyoto 602-0857, Japan. Email: uchino@koto.kpu-m.ac.jp.

Provenance: This is an invited article commissioned by the Section Editor Jun Zhou, MD (Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China).

Comment on: Cho BC, Chewaskulyong B, Lee KH, et al. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. J Thorac Oncol 2019;14:99-106.


Submitted Mar 07, 2019. Accepted for publication Mar 13, 2019.

doi: 10.21037/tlcr.2019.03.06


The discovery of the epidermal growth factor receptor (EGFR) gene as the first driver gene in lung cancer has led to a major paradigm shift in lung cancer treatment. Gefitinib and other EGFR-tyrosine kinase inhibitors (TKIs) have demonstrated excellent antitumor activity against EGFR mutation-positive non-small cell lung cancer (NSCLC). However, resistance to TKI emerged over the course of treatment, and resistance due to T790M mutations was noted in approximately half of the cases (1,2).

Subsequently, the efficacy of treatment with osimertinib was confirmed in T790M mutation-positive cases resistant to EGFR-TKI, and further, FLAURA studies reported the usefulness of primary treatment with osimertinib in untreated EGFR mutation-positive cases (3,4).

The FLAURA trial is a randomized controlled trial of osimertinib compared to standard-of-care (gefitinib or erlotinib) to evaluate the efficacy and safety of osimertinib in patients with advanced-stage EGFR mutation-positive lung cancer. In a study of 556 patients, including 62% Asians, the primary endpoint of median progression-free survival (PFS) was 18.9 months in the osimertinib group (n=279) and 10.2 months in the conventional group (n=277), showing a significantly higher PFS with osimertinib in the initial treatment. Our results further highlighted the efficacy of osimertinib as a first-line treatment for EGFR mutation-positive lung cancer.

This study reports an Asian subset analysis of the FLAURA trial. Of the total 556 patients, 323 Asian patients had PFS of 16.5 months in the osimertinib group and 11 months in the standard-of-care group (HR, 0.54; 95% CI, 0. 41 to 0.72; P<0.0001), indicating a significant beneficial effect of osimertinib in Asian patients. Furthermore, osimertinib was almost as safe as the standard-of-care drug in this study, and serious adverse events of Grade 3 or higher were lower (40% vs. 48%) than those in the standard-of-care group. We conducted a prospective clinical study of osimertinib (phase II, recurrent EGFR-positive NSCLC, T790M-positive cases, n=36) in elderly patients (75 years of age or older) in Japan, and found that the disease control rate was 93%. Malaise (38.9%) and diarrhea (36.1%) were the common adverse events, but good results have also been observed with regard to efficacy and tolerability in the elderly (5).

The usefulness of EGFR-TKI in Asians has been reported.

The OPTIMAL trial, a randomized controlled trial of chemotherapy and erlotinib for Exon19-deletion or L858R-positive cases conducted at 22 Chinese institutions, reported a significantly better PFS of 13.1 months (4.6 months in the chemotherapy arm) in the erlotinib arm (6). In addition, the PFS of afatinib was 11.1 months overall and 13.8 months in the Japanese population in the LUX-Lung 3 trial, a randomized controlled trial of chemotherapy and afatinib that included approximately 70% Asians. The non-Asian HR of 0.62 (95% CI, 0.36 to 1.06) also did not differ significantly from the Asian HR of 0.45 (95% CI, 0.33 to 0.62) (P=0.62) in terms of overall survival (OS), suggesting a higher efficacy in Asians (7). Regarding afatinib, in a combined analysis of LUX-Lung 6 examining the usefulness of afatinib in Asian regions and the aforementioned LUX-Lung 3, an examination of the OS following standard chemotherapy revealed a significantly longer OS in patients with del19 mutations, suggesting that EGFR-TKI sensitivity varies not only by ethnicity but also by genetic mutation patterns (8,9).

EGFR mutations are reported in 40–50% of lung adenocarcinomas in East Asians but in as low as 15% of North Americans and Europeans, suggesting regional differences in genetic background. A recent study has strongly suggested the use of may have established osimertinib as a primary treatment for EGFR-positive cases, particularly in Asians (10).

Meanwhile, the effectiveness of osimertinib for cases with brain metastasis has been reported. Ballard et al. have reported that osimertinib is efficacious in simian models of brain metastases (11). Given these results, the FLAURA trial included a subset analysis of brain metastases and provided valuable prospective data on the treatment of brain metastasis cases with TKIs. Previously, erlotinib, an EGFR-TKI, was suggested to be marginally effective in patients with brain metastases, but the results were not statistically significant (12). Although current data are premature, osimertinib significantly prolonged PFS in patients with brain metastases compared to standard-of-care. However, the number of patients with brain metastases in this Asian cohort was relatively small, about 20%. Despite its seemingly superior efficacy, the difference between the treatment groups was not statistically significant. Furthermore, although the osimertinib group tended to show improved OS, it should be noted that further follow-up reports are pending. Overall, the low transition rates post treatment in the osimertinib group (63%) and in the standard-of-care group (58%), may reflect medical economy in Asia and should be interpreted with caution.

Given the favorable results of the FLAURA trials, the use of the drugs investigated therein as the first-line therapy in patients with positive EGFR mutations will continue to be discussed. The total PFS was expected to be more than 20 months if first-line treatment was initiated with conventional EGFR-TKI and second-line treatment with osimertinib in T790M positive cases (9,13,14). This figure may be greater than the PFS achieved with osimertinib as first-line therapy. In addition, the efficacy of dacomitinib over gefitinib in ARCHER1050 (OS 34.1 vs. 26.8 months) suggests that, except for adverse events and tolerability issues, dacomitinib may be the better choice as first-line treatment (15). It has also been suggested that second-generation TKI such as afatinib and dacomitinib are more efficacious than first-generation TKI for cases with uncommon mutations (9).

It has been reported that the incidence of T790M with the use of conventional EGFR-TKI as first-line treatment is similar to, or marginally lower than, that observed with gefitinib, erlotinib, and afatinib as first-line therapy (16,17). The incidence of T790M after dacomitinib administration is unknown and is expected to be reported in the future. Thus, the incidence of T790M influences the selection of the EGFR-TKI for primary treatment. Future studies will focus on predicting T790M-positive cases.

Moreover, the effectiveness of the combined use of various treatments, except for EGFR-TKI, has recently been demonstrated, and the effectiveness and safety of the combined use of immune checkpoint inhibitors (ICI), radiotherapy, and platinum doublet have also been evaluated. The usefulness of combination therapy with gefitinib and platinum doublet has been shown in Japan, and similar effects may be expected with osimertinib (18).

Although programmed cell death ligand 1 (PD-L1) and tumor mutation burden (TMB) were not measured in this study, the efficacy of EGFR-TKI treatment was found to be significantly worse in cases with EGFR mutation positive and PD-L1-tumor proportion score (TPS) of 1% or more (19). Furthermore, atezolizumab significantly improved PFS when used in combination with chemotherapy after EGFR-TKI treatment in EGFR mutation-positive cases (20). Based on these reports, selection of therapeutic agents other than EGFR-TKI may be crucial in patients with elevated PD-L1 expression. For patients with EGFR mutation positivity and a PD-L1 TPS of 1% or more, treatment strategies may include the use of a combination of atezolizumab and platinum doublet after EGFR-TKI therapy and second-line therapy. Thus, the efficacy of ICI as post-treatment in EGFR mutation-positive cases will be noticed in the future. However, the effectiveness of atezolizumab in EGFR mutation-positive patients has not been demonstrated in the OAK study, and further studies are needed.

I am very pleased that this study confirmed the high efficacy and safety of osimertinib in Asians. In the future, it is expected that individualized treatment will become possible upon the establishment of various biomarkers and advancement in comprehensive gene analysis.


Acknowledgments

None.


Footnote

Conflicts of Interest: J Uchino received grants from AstraZeneca K.K. The funder had no role in the writing of the manuscript. The other authors have no conflicts of interest to declare.


References

  1. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. [Crossref] [PubMed]
  2. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. [Crossref] [PubMed]
  3. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35:3484-515. [Crossref] [PubMed]
  4. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR -Mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113-25. [Crossref] [PubMed]
  5. Nakao A, Hiranuma O, Uchino J, et al. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. Oncologist 2019. [Epub ahead of print]. [Crossref] [PubMed]
  6. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42. [Crossref] [PubMed]
  7. Yang JC, Hirsh V, Schuler M, et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013;31:3342-50. [Crossref] [PubMed]
  8. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213-22. [Crossref] [PubMed]
  9. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51. [Crossref] [PubMed]
  10. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985-93. [PubMed]
  11. Ballard P, Yates JW, Yang Z, et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res 2016;22:5130-40. [Crossref] [PubMed]
  12. Li MX, He H, Ruan ZH, et al. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer 2017;17:245. [Crossref] [PubMed]
  13. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009;361:947-57. [Crossref] [PubMed]
  14. Mitsudomi T. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? Lancet Oncol 2011;12:710-1. [Crossref] [PubMed]
  15. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:1454-66. [Crossref] [PubMed]
  16. Jenkins S, Chih-Hsin Yang J, Jänne PA, et al. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. J Thorac Oncol 2017;12:1247-56. [Crossref] [PubMed]
  17. Nosaki K, Satouchi M, Kurata T, et al. Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer 2016;101:1-8. [Crossref] [PubMed]
  18. Nakamura A, Inoue A, Morita S, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol 2018;36:abstr 9005.
  19. Yoneshima Y, Ijichi K, Anai S, et al. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer 2018;118:36-40. [Crossref] [PubMed]
  20. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018;378:2288-301. [Crossref] [PubMed]
Cite this article as: Onoi K, Kaneko Y, Uchino J. Osimertinib in first line setting: for Asian patients. Transl Lung Cancer Res 2019;8(4):550-552. doi: 10.21037/tlcr.2019.03.06